Secondly, numerous experiments have shown that histone deacetylase (HDAC) inhibitors can activate the FMR1 gene and ameliorate FXS symptoms, even without altering DNA methylation activity (Biacsi et al., 2008; Tabolacci et al., 2008). The gene discussed is FMR1; the disease is fragile X syndrome.